Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617

Prostate cancer (PC) is one of the most common malignancies affecting men, with poor prognosis after progression to metastatic castration-resistant prostate cancer (mCRPC). Radioligand therapy (RLT) targeting the overexpressed PSMA on PC cells, with, e.g., <sup>177</sup>Lu-PSMA-617, has...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Amanda Kristiansson, Oskar Vilhelmsson Timmermand, Mohamed Altai, Joanna Strand, Sven-Erik Strand, Bo Åkerström, Anders Örbom
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI AG 2022-03-01
Saila:Pharmaceutics
Gaiak:
radioligand therapy
<sup>177</sup>Lu-PSMA-617
prostate cancer
mouse model
hematotoxicity
Sarrera elektronikoa:https://www.mdpi.com/1999-4923/14/4/731
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak